COPENHAGEN, Denmark, Feb. 5, 2015 (GLOBE NEWSWIRE) — Forward Pharma A/S (FWP), a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, today announced that Joel Sendek, Forward Pharma’s Chief Financial Officer, will present at the following conferences:
- The Leerink Global Healthcare Conference to be held at the Waldorf Astoria in New York, New York. Joel Sendek will present on Thursday, February 12th at 10:45 AM EDT.
- The RBC Capital Markets’ 2015 Global Healthcare Conference to be held at the Palace Hotel in New York, New York. Joel Sendek will present on Tuesday, February 24th at 8:30 AM EDT.
Investors and other interested parties may access a live audio webcast of the conference presentations by visiting Forward Pharma’s website at www.forward-pharma.com. The audio replay will be available via our website for 90 days post the presentation.
About Forward Pharma:
Forward Pharma A/S is a Danish biopharmaceutical company (the “Company or “Forward Pharma”) developing FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications. Since our founding in 2005, we have worked to advance unique formulations of DMF, an immune modulator, as a therapeutic to improve the health and well-being of patients with immune disorders including MS. FP187, our clinical candidate, is a DMF formulation in a delayed and slow release oral dose, which we plan to advance for the treatment of relapsing remitting MS, or RRMS, and other immune disorders, such as psoriasis.
Our principal executive offices are located at OEstergade 24A, 1, 1100 Copenhagen K, Denmark and our American Depositary Shares are publicly traded on NASDAQ Stock Market (FWP). For more information about the Company’s products and developments, please visit our web site at www.forward-pharma.com.
Forward Looking Statements:
Certain statements in this press release may constitute “forward-looking statements” of the Company within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to: statements which contain language such as: “believe,” “expect,” “hope,” “would” and “potential.” Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: the Company’s ability to obtain, maintain and defend issued patents with protective claims; the commencement of any patent interference or infringement action; the Company’s ability to prevail in or obtain a favorable decision in any such action; and the Company’s ability to recover damages in any such action; uncertainties relating to our development plans; risks and uncertainties related to the scope, validity; and the enforceability of our intellectual property rights in general and the impact on us of patents and other intellectual property of third parties. Given the uncertainties, assumptions and risk factors associated with this type of information, including those described above, investors are cautioned that the information may not be appropriate for other purposes.
- Health Care Industry
- Investment & Company Information
- immune disorders
Source Article from http://finance.yahoo.com/news/forward-pharma-cfo-present-two-133000983.html
Forward Pharma CFO to Present at Two Upcoming Conferences in February
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results